[Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis].
Desmopressin (DDAVP) is an effective tool for increasing factor VIII (FVIII)/von Willebrand factor (vWF) in normal subjects and in patients with haemophilia A and von Willebrand's disease. There are a few studies utilizing DDAVP to increase the FVIII/vWF yield in plasmapheresis donors. In these studies, DDAVP was given either by intranasal administration or intravenous infusion. The aim of our pilot study was to investigate the subcutaneous (s.c.) injection of DDAVP in combination with double bag plasmapheresis. 8 donors with blood group A and 5 with O were given 0.4 micrograms/kg body weight DDAVP as a s.c. injection 30 min prior to the first donation. FVIII increased 3.7 and ristocetin cofactor 2.5 the initial value in the donors. In the plasma bags, a 3 (1st bag) and 3.5 (2nd bag) fold higher FVIII level was found, when compared with baseline levels. There was only a mild decrease of blood pressure, and serious adverse effects were not observed. Our data suggest that s.c. DDAVP may be more effective and especially suited for increasing FVIII/vWF yield in plasmapheresis donors.
Köhler
M
M
Abteilung für klinische Hämostaseologie und Transfusionsmedizin, Universität des Saarlandes.
Kotitschke
R
R
Braun
B
B
Hellstern
P
P
Mörsdorf
S
S
Pindur
G
G
Heiden
M
M
Wenzel
E
E
D001782:Blood Donors; D001794:Blood Pressure / Q000187:drug effects; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage*; D005169:Factor VIII / Q000378:metabolism*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007279:Injections, Subcutaneous; D010956:Plasmapheresis; D014841:von Willebrand Factor / Q000378:metabolism*
D014841:von Willebrand Factor; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin
Subkutan injiziertes Desmopressin (DDAVP) zur Erhöhung des Faktors VIII und von-Willebrand-Faktors bei Plasmapherese.